2 weeks Ago By Defense World Staff
Rhumbline Advisers bought a new stake in Eliem Therapeutics, Inc. ( NASDAQ:ELYM – Free Report ) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 8,233 shares of the company’s stock, valued at approximately $59,000.
Separately, Bank of New York Mellon Corp acquired a new position in shares of Eliem Therapeutics in the second quarter valued at approximately $134,000. Institutional investors own 69.76% of the company’s stock.
Eliem Therapeutics Trading Up 2.2 % ELYM stock opened at $5.09 on Tuesday.
The stock has a 50-day moving average price of $7.09 and a two-hundred day moving average price of $6.56.
Eliem Therapeutics, Inc. has a 1 year low of $2.35 and a 1 year high of $11.
55. The stock has a market cap of $151.44 million, a PE ratio of -9.
60 and a beta of -0.35. Insider Buying and Selling at Eliem Therapeutics In other news, EVP Valerie Morisset sold 69,005 shares of the business’s stock in a transaction dated Monday, July 22nd.
The shares were sold at an average price of $8.03, for a total value of $554,110.15.
Following the completion of the sale, the executive vice president now owns 31,317 shares of the company’s stock, valued at $251,475.51. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink .
Insiders have sold a total of 294,254 shares of company stock valued at $2,137,260 in the last three months. 4.70% of the stock is currently owned by company insiders.
Eliem Therapeutics Company Profile ( Free Report ) Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware. See Also Five stocks we like better than Eliem Therapeutics What is a SEC Filing? TJX Stock: A Buying Opportunity Before the Holiday Rush Using the MarketBeat Dividend Yield Calculator Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge How to Calculate Inflation Rate Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Want to see what other hedge funds are holding ELYM? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Eliem Therapeutics, Inc. ( NASDAQ:ELYM – Free Report ). Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
